Neuroguard IEP 3-in-1 Carotid Stent and Post- Dilatation Balloon System with Integrated Embolic Protection
Contego Medical, Inc. · Decision date May 8, 2026
What did the FDA decide?
FDA records P240009/S008 as a supplement to PMA P240009, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 8, 2026.
FDA approval order statement
removal of destructive testing at product release and updated in-process monitoring
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- May 8, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P240009/S008
- Regulatory pathway
- PMA supplement
- Applicant
- Contego Medical, Inc.
- Product code
- NIM
- Decision code
- OK30
- Decision date
- May 8, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent, carotid.
- Applicant
- Contego Medical, Inc.
- Product code
- NIM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240009. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240009 · Original PMA
Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
P240009/S004 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
P240009/S005 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilation Balloon System with Integrated Embolic Protection (Neuroguard I
P240009/S007 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent and Post- Dilatation Balloon System with Integrated Embolic Protection
P240009/S008 received
Application receipt date recorded by FDA.
P240009/S008 · FDA decision
30-Day Notice
P240009/S011 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
P240009/S012 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent and Post-Dilatation Balloon System with Integrated Embolic Protection
P240009/S006 · Related supplement
Neuroguard IEP 3-in-1 Carotid Stent, Post-Dilation Balloon System with Integrated Embolic Protection
Timeline entries are records held by MedtechLedger for P240009. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240009
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Contego Medical, Inc. | PMA approval | Oct 11, 2024 | FDA | |
| Contego Medical, Inc. | PMA supplement | Aug 22, 2025 | FDA | |
| Contego Medical, Inc. | PMA supplement | Sep 19, 2025 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jan 28, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | May 27, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Jul 29, 2026 | FDA | |
| Contego Medical, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code NIM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROTEGE GPS AND PROTEGE RX CAROTID STENT SYSTEMSP060001/S060 | Medtronic Vascular, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| Medtronic Vascular, Inc. | PMA supplement | Oct 16, 2026 | FDA | |
| Medtronic Vascular, Inc. | PMA supplement | Jul 10, 2026 | FDA | |
Roadsaver/CASPER Carotid Stent SystemP210030/S002 | Microvention, Inc. | PMA supplement | Jul 7, 2026 | FDA |
PRECISE PRO RX Nitinol Stent SystemP030047/S055 | Cordis US Corporation | PMA supplement | Jun 5, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Contego Medical, Inc.
- Headquarters
- Not reported
- Brand website
- contegomedical.com
- FDA applicant address
- 3801 Lake Boone Trl., Suite 100, Raleigh, NC, 27607
Sources and methodology
- Original FDA record: P240009/S008
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




